CD86 and neoplasm: Additionally, preS1‐pHLIP NMs treatment recruited significant numbers of CD3+CD8+ T cells, CD49B+ NK cells, F4/80+CD86+ M1‐polarized macrophages, CD80+CD86+ DC cells and CD11B+Ly6G+ neutrophils into the tumor tissue (Figure 6g–j).